Ulcerative colitis-associated colorectal cancer

doi:10.3748/wjg.v20.i44.16389

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 44

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16828)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

1513

WORD

301

HTML

12291

Tables (1-2)

144

Sum=14249

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1358

Download

1221

Sum=2579

Nov 28, 2014 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (179)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 28, 2014; 20(44): 16389-16397
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16389

Ulcerative colitis-associated colorectal cancer

Masakazu Yashiro

Masakazu Yashiro, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

Masakazu Yashiro, Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

Author contributions: Yashiro M solely contributed to the manuscript.

Correspondence to: Masakazu Yashiro, MD, PhD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp

Telephone: +81-6-66453838 Fax: +81-6-66466450

Received: May 27, 2014
Revised: September 15, 2014
Accepted: October 14, 2014
Published online: November 28, 2014

Abstract

The association between ulcerative colitis (UC) and colorectal cancer (CRC) has been acknowledged. One of the most serious and life threatening consequences of UC is the development of CRC (UC-CRC). UC-CRC patients are younger, more frequently have multiple cancerous lesions, and histologically show mucinous or signet ring cell carcinomas. The risk of CRC begins to increase 8 or 10 years after the diagnosis of UC. Risk factors for CRC with UC patients include young age at diagnosis, longer duration, greater anatomical extent of colonic involvement, the degree of inflammation, family history of CRC, and presence of primary sclerosing cholangitis. CRC on the ground of UC develop from non-dysplastic mucosa to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of UC-CRC. 5-aminosalicylates might represent a favorable therapeutic option for chemoprevention of CRC.

Keywords: Ulcerative colitis-associated colorectal cancer, Risk factor, Dysplasia, Surveillance colonoscopy, Chemoprevention

Core tip: Colorectal cancer (CRC) is more frequent in patients with long-term ulcerative colitis (UC), and is one of the most serious and life threatening consequences of UC. Knowledge of risk factors for CRC is important to identify UC patients who need surveillance. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of CRC in UC patients. 5-aminosalicylates might represent a favorable therapeutic option for chemoprevention of CRC.